CREATE Medicines Inc, a clinical-stage biotechnology company, announced on Friday that it has entered into a strategic research collaboration with Australia's Monash University and its Monash Institute of Pharmaceutical Sciences (MIPS).

This collaboration expands CREATE's portfolio by accessing Monash's advanced lipid nanoparticle (LNP) technology including proprietary binders and chemistry, strengthening its ability to develop best-in-class targeted in vivo therapies.

Together, CREATE and MIPS will jointly advance targeted Chimeric Antigen Receptor (CAR) therapy, with the aim of allowing precise, cell-type-specific in vivo delivery of CAR payloads using the targeted LNP technology.

Under the agreement, CREATE receives a worldwide exclusive licence to all intellectual property arising from the collaboration, together with the right to develop and commercialise CAR products directed to designated CAR targets. MIPS will receive research funding and downstream milestone and royalty payments.